Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

87 results about "Gene knockin" patented technology

In molecular cloning and biology, a knock-in (or gene knock-in) refers to a genetic engineering method that involves the one-for-one substitution of DNA sequence information in a genetic locus or the insertion of sequence information not found within the locus. Typically, this is done in mice since the technology for this process is more refined and there is a high degree of shared sequence complexity between mice and humans. The difference between knock-in technology and traditional transgenic techniques is that a knock-in involves a gene inserted into a specific locus, and is thus a "targeted" insertion.

Exogenous gene knocking-in and integrating system on basis of CRISPR/Cas9, method for establishing exogenous gene knocking-in and integrating system and application thereof

The invention provides an exogenous gene knocking-in and integrating system on the basis of CRISPR/Cas9, a method for establishing the exogenous gene knocking-in and integrating system and application thereof. The exogenous gene knocking-in and integrating system comprises vectors with report/donor functions and Cas9 expression vectors. Each report/donor vector comprises two target gent homologous arms and an exogenous sequence fragment positioned between the two target gene homologous arms; homologous sequences, which are positioned on a target gene, of the two target gene homologous arms of each report/donor vector are respectively positioned on two sides of a target sequence of the target gene and are connected with the target sequence of the target gene; the exogenous sequence fragments comprise promoters, resistant genes, shorn peptide sequences, report genes and polyA tails which are sequentially arrayed, two SSA repair homologous sequences of each resistant gene are inserted into the resistant gene, and the target sequence of each target gene is inserted in a space between the two corresponding SSA repair homologous sequences. The exogenous gene knocking-in and integrating system, the method and the application have the advantages that exogenous genes can be integrated with endogenous gene sequences in an efficient site-directed and accurately targeted manner, and double-chromosome allelic gene double-knocking-in can be efficiently carried out.
Owner:成都中科奥格生物科技有限公司

Recombinant vector for knock-in of human Huntington gene, construction method of recombinant vector and application of recombinant vector in construction of model pig

ActiveCN107988256AIncreased probability of knock-in positive clonesEfficient FeasibilityStable introduction of DNANucleic acid vectorHuman studiesExon
The invention discloses a recombinant vector for the knock-in of a human Huntington gene, a construction method of the recombinant vector and application of the recombinant vector in the constructionof a model pig. According to the recombinant vector, a human mutated Huntington exon gene is knocked in a fixed point manner for the first time, a virulence gene is knocked in by virtue of a CRISPR / Cas9 technique for the first time, and a donor vector is optimized by optimizing sfRNA, so that the probability that the gene is knocked into a positive cloned cell is increased; and by combining with apig cell nucleus transplantation technique, the probability that a directly obtained positive cell is knocked into the pig is increased, and a small human Huntington gene knock-in pig is obtained, thereby proving the efficient feasibility of the method for constructing gene modified pigs. The constructed Huntington gene knock-in model pig has behavioral characteristics such as respiratory disturbance and dyskinesia similar to human Huntington diseases, and stable heritable passage can be realized, so that a reliable model is provided for the research of the human Huntington diseases; and thenumber can be guaranteed so as to realize drug screening, gene treatment, stem cell treatment and the like, and the model can be a good human disease model.
Owner:JINAN UNIVERSITY +1

Method for preparing general type CAR-T cells by using CRISPR/Cas9+AAV

InactiveCN109609551AImprove safety and controlReduce treatment time cost and capital costMammal material medical ingredientsBlood/immune system cellsCAR T-cell therapyAdeno-associated virus
The invention relates to a method for preparing general type CAR-T cells by using CRISPR / Cas9+AAV, and belongs to the field of immunocytotherapy. The method utilizes CRISPR / Cas9+AAV to knock out an immunological checkpoint PD-1, a human leukocyte antigen (HLA) and TCR; multi-gene knockout is employed to prepare the general type CAR-T cells; and a CRISPR / Cas9 gene editing technology is used to perform precise gene knockout, and is used in combination with adeno-associated virus (AAV) to replace lentiviruses for precise gene knock-in and to avoid the potential risk of random integration of the lentiviruses. The method of the invention can realize multi-target gene knock-in and knock-out, construct the general type CAR-T cells for allogeneic treatment, and solve the problems existing in traditional CAR-T cell therapy such as risk of random insertion mutation of lentiviruses, high production cost and long preparation period for autologous CAR-T design and culture, and insufficient cell number and expansion ability.
Owner:广州白云山拜迪生物医药有限公司

High-efficient accurate targeted gene integration system and application thereof

The invention discloses a high-efficient accurate targeted gene integration system and an application thereof. The high-efficient accurate targeted gene integration system comprises an expression exogenous fusion protein system, a guide RNA and a donor carrier, wherein the expression exogenous fusion protein system comprises a fusion protein formed by one of Cas9 or SB or Cas9 and SB, N123, N57 and SB100XE279D; the guide RNA is a long sequence of 20bp in a target genome region and two ends of the donor carrier; and two ends of the donor carrier guide RNA targeted sites, SB binding sites and middle target gene integration fragments are arranged at two ends of the donor carrier. Through the adoption of the high-efficient accurate targeted gene integration system disclosed by the invention, the targeting, the cutting and the integrating of gene can be simultaneously realized; and SB transposase is utilized to be combined with a transposon donor to form a tetramer, so that the donor carrier can be oriented to the target sites, and targeted integration of the gene is facilitated. According to the high-efficient accurate targeted gene integration system disclosed by the invention, in vivo linearization elements are utilized, so that in vitro linearization of the donor carrier can be realized, and the integration of the genes is facilitated; and the method for realizing gene typing isbased on the SB transposase and NHEJ in a gene repairing mechanism, so that the high-efficient accurate targeted gene integration system can realize gene integration efficiently.
Owner:SOUTHERN MEDICAL UNIVERSITY

Method used for discovering and identifying liver cancer serum differential expression proteins and verifying marker proteins

The invention discloses a method used for discovering and identifying liver cancer serum differential expression proteins and verifying marker proteins. According to the method, iTRAQ labeling MALDI-TOF MS / MS technology is adopted for discovering and identifying liver cancer serum differential expression proteins and MRM verifying of marker proteins. According to the method, searching on effectivetumor markers possesses important meaning on canceration mechanism study, disease early stage diagnosis, and prognosis. Selected novel liver cancer protein markers are subjected to in vivo and in vitro experiments such as gene knockin and knockout, and nude mice transplanted cancer, influences of blocking or up-regulating of expression of candidate genes on tumor biological behavior are observed,and key proteins capable of influencing human liver cancer occurrence and development are positioned, the effects of the key proteins in a system signal network is analyzed based on bioinformatics analysis, and the feasibility, the liver cancer diagnosis value, and the clinical significance of the key proteins in clinical applications including liver cancer prevention, early stage diagnosis, andprognosis is evaluated based on MRM absolute quantitative verification.
Owner:南宁科城汇信息科技有限公司

Escherichia coli for arsenic detection

ActiveCN104894042AReduce the background valueHigh background valueBacteriaMicrobiological testing/measurementEscherichia coliFluorescence
The invention relates to a microorganism method for detecting metallic-arsenic-like in water, in particular to an escherichia coli report bacterial strain culturing method improved through genetic engineering, and an escherichia coli culturing method for detecting arsenic in water. The detection bacterial strain is obtained by adopting a Red recombination system to knockout arsenic resistant arsB genes of wild type escherichia coli MC4100, and then adopting the gene knockin technology to substitute pars-arsR-gfpmut2 report genes to the positions of araB coding genes. The biological detection bacterial strain is named as E.coli WMC-011p. The lowest arsenic detection range meets the Integrated Wastewater Discharge Standard of GB8978-1996. The bacterial strain overcomes the shortcomings of high fluorescence background value, unstable detection signals, inaccurate results and the like of a biological detection bacterial strain based on a plasmid vector, and has the advantages of high specificity, high sensitivity, low cost and the like.
Owner:WENZHOU MEDICAL UNIV

Gene knockin method and kit for gene knockin

InactiveUS20190225989A1Efficient preciseHydrolasesStable introduction of DNAGene knockinEndonuclease
A gene knockin method and a kit for gene knockin are provided. The method comprises (a) introducing a RNA-guided endonuclease that cleaves the chromosome at the insertion site into the cell; (b) introducing a guide RNA into the cell; and (c) introducing a donor plasmid into the cell, wherein the donor plasmid comprises the donor sequence flanked with a 5′ homology arm and a 3′ homology arm, a 5′ flanking sequence upstream of the 5′ homology arm, and a 3′ flanking sequence downstream of the 3′ homology arm, wherein the 5′ homology arm is homologous to a 5′ target sequence upstream of the insertion site on the genome and the 3′ homology arm is homologous to a 3′ target sequence downstream of the insertion site on the genome, wherein the guide RNA recognizes the insertion site, the 5′ flanking sequence, and the 3′ flanking sequence, wherein the RNA-guided endonuclease cleaves the donor plasmid at the 5′ flanking sequence and the 3′ flanking sequence, thereby producing a linear nucleic acid, wherein the donor sequence is inserted in to the genome at the insertion site through homology-directed repair.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CAMS & PUMC

Gene knock-in non-human animal

The present invention provides a non-human animal in which a DNA comprising an hp7 sequence-encoding DNA and a poly A addition signal-encoding DNA added on the 3' side of a DNA encoding an arbitrary foreign gene is inserted in the same reading frame as that of an arbitrary target gene present on the genome of the non-human animal.
Owner:CHUGAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products